Evidence map›Paper›PMID 28486662›Full record

ArticleRheumatology (Oxford, England)2017

Elevated ACKR2 expression is a common feature of inflammatory arthropathies.

Helen M Baldwin, Mark D Singh, Veronica Codullo, Vicky King, Hilary Wilson, Iain McInnes, Gerard J Graham

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Helen M BaldwinInstitute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Mark D SinghInstitute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Veronica CodulloInstitute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Vicky KingInstitute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Hilary WilsonInstitute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Iain McInnesInstitute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Gerard J GrahamInstitute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Funding

Arthritis Research UK 18448Medical Research Council G0901113Medical Research Council MR/M019764/1Wellcome TrustWellcome Trust 099251/Z/12/Z
6 · The paper itself

Abstract

Objectives: Chemokines are essential contributors to leucocyte accumulation at sites of inflammatory pathology. Interfering with chemokine or chemokine receptor function therefore represents a plausible therapeutic option. However, our currently limited understanding of chemokine orchestration of inflammatory responses means that such therapies have not yet been fully developed. We have a particular interest in the family of atypical chemokine receptors that fine-tune, or resolve, chemokine-driven responses. In particular we are interested in atypical chemokine receptor 2 (ACKR2), which is a scavenging receptor for inflammatory CC-chemokines and that therefore helps to resolve in vivo inflammatory responses. The objective of the current study was to examine ACKR2 expression in common arthropathies. Methods: ACKR2 expression was measured by a combination of qPCR and immuno-histochemistry. In addition, circulating cytokine and chemokine levels in patient plasma were assessed using multiplexing approaches. Results: Expression of ACKR2 was elevated on peripheral blood cells as well as on leucocytes and stromal cells in synovial tissue. Expression on peripheral blood leucocytes correlated with, and could be regulated by, circulating cytokines with particularly strong associations being seen with IL-6 and hepatocyte growth factor. In addition, expression within the synovium was coincident with aggregates of lymphocytes, potentially atopic follicles and sites of high inflammatory chemokine expression. Similarly increased levels of ACKR2 have been reported in psoriasis and SSc. Conclusion: Our data clearly show increased ACKR2 in a variety of arthropathies and taking into account our, and others', previous data we now propose that elevated ACKR2 expression is a common feature of inflammatory pathologies.

Indexed as

AdultAgedArthritis, PsoriaticArthritis, RheumatoidBiomarkersCase-Control StudiesCells, CulturedChemokine Receptor D6ChemokinesCytokinesFemaleHumansLeukocytes, MononuclearMaleMiddle AgedReceptors, ChemokineACKR2 protein, humanBiomarkersChemokine Receptor D6ChemokinesCytokinesReceptors, ChemokineACKR2arthritischemokineinflammation

Identifiers

PMID28486662
PMCPMC5850605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.